T-cell therapy for progressive multifocal leukoencephalopathy (PML)
Part of Brain & nervous system, Infections clinical trials.
This trial tests a T-cell therapy for people with PML, a rare brain infection. It aims to boost your immune system to fight the virus causing PML. You may be eligible if you have PML not caused by HIV, natalizumab, or certain recent treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with PML in the last 60 days.
- Your PML is linked to conditions like lymphoma, immune-suppressing drugs, or low white blood cells.
- The virus causing PML is confirmed in your spinal fluid or brain tissue.
- You cannot have HIV or PML caused by the drug natalizumab.
- You have not received a stem cell transplant or CAR T-cell therapy in the last 5 years.
- You are not pregnant, breastfeeding, or on chemotherapy currently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pembrolizumab, an immunotherapy drug, can help fight a rare brain virus called PML in people whose immune systems are weakened but not due to HIV. The goal is to see if it improves recovery.
This study follows people with suspected or confirmed progressive multifocal leukoencephalopathy (PML), people at higher risk, and healthy volunteers. It uses visits, brain imaging (MRI), and stored biological samples to better understand how PML progresses and who is at risk.
This pilot study tests an IV medicine called brincidofovir for people with PML, a serious brain infection. The goal is to see if it can stop the virus from causing more damage.
This study follows patients with chronic viral infections affecting the brain and spinal cord. Researchers will collect spinal fluid samples and track your health over one year to better understand these infections and improve care.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests a new treatment where your own immune cells (T cells) are collected, activated, and then injected into the fluid around your brain and spinal cord to fight melanoma cells that have spread there. It's for people whose melanoma has traveled to the lining of the brain or spinal cord (leptomeningeal disease).
Hear when a new Progressive Multifocal Leucoencephalopathy (PML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.